We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Ascendis Hit With CRL Over Variability in Delivered Dose in Drug/Device Combo
Ascendis Hit With CRL Over Variability in Delivered Dose in Drug/Device Combo
Ascendis Pharma of Denmark got slapped with a Complete Response Letter (CRL) in which the FDA voiced concerns about the variability in the delivered dose of the company’s investigational treatment for adults with hypoparathyroidism.